Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of SRX246, a Vasopressin Receptor (V1a) Antagonist, on an Experimental Model of Fear and Anxiety in Humans

NCT02922166 is registered in ClinicalTrials.gov with Azevan Pharmaceuticals as lead sponsor.

NCT NCT02922166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02922166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of SRX246, a Vasopressin Receptor (V1a) Antagonist, on an Experimental Model of Fear and Anxiety in Humans
Lead sponsor
Azevan Pharmaceuticals
Phase
Phase 1
Overall status
Unknown status
Start date
February 3, 2017
Completion date
December 31, 2019
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety, fear